Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 5, 2015, Pages 665-672

  Serdjebi, Cindy ^a   Milano, Gérard ^b   Ciccolini, Joseph ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b OGC Nice   (France)

Author keywords

Adaptive dosing strategy; Cytidine deaminase; Nucleosidic analogs; Pharmacogenetics

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; 5' DEOXY 5 FLUOROCYTIDINE; 6 AZACITIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTARABINE; CYTIDINE DEAMINASE; CYTIDINE DERIVATIVE; CYTOTOXIC AGENT; DECITABINE; DOCETAXEL; DOXIFLURIDINE; FAZARABINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; NUCLEOSIDE ANALOG; TETRAHYDROURIDINE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; NUCLEOSIDE;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACODYNAMICS; REVIEW; TREATMENT OUTCOME; ADULT; ANIMAL; CHILD; GENETIC POLYMORPHISM; GENETICS; METABOLISM; NEOPLASMS;

ADULT; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CYTIDINE DEAMINASE; GENOTYPE; HUMANS; NEOPLASMS; NUCLEOSIDES; POLYMORPHISM, GENETIC;

EID: 84928897022     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.985648     Document Type: Review

References (58)

1. Ciccolini J, Mercier C, Dahan L, Andre N. Integrating pharmacogenetics into gemcitabine dosing-time for a change? Nat Rev Clin Oncol 2011;8(7):439-44
2. Kirch HC, Schroder J, Hoppe H, et al. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998;26(5):421-5
3. Yue L, Saikawa Y, Ota K, et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003;13(1):29-38
4. Ciccolini J, Evrard A, M'Batchi L, et al. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics 2012;13(4):393-7
5. Micozzi D, Carpi FM, Pucciarelli S, et al. Human cytidine deaminase: a biochemical characterization of its naturally occurring variants. Int J Biol Macromol 2014;63:64-74.
6. Schroder JK, Kirch C, Seeber S, Schütte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 1998;103(4):1096-103
7. Teng YS, Anderson JE, Giblett ER. Cytidine deaminase: a new genetic polymorphism demonstrated in human granulocytes. Am J Hum Genet 1975;27(4):492-7
8. Fitzgerald SM, Goyal RK, Osborne WR, et al. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 2006;119(3):276-83
9. Gilbert JA, Salavaggione OE, Ji Y, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006;12(6):1794-803
10. Giovannetti E, Laan AC, Vasile E, et al. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008;27(6):720-5.
11. Ludovini V, Floriani I, Pistola L, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabinetreated advanced non-small cell lung cancer patients. J Thorac Oncol 2011;6(12):2018-26
12. Maring JG, Wachters FM, Slijfer M, et al. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010;66(6):611-17
13. Mercier C, Dupuis C, Blesius A, et al. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother Pharmacol 2009;63(6):1177-80.
14. Parmar S, Seeringer A, Denich D, et al. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. Pharmacogenomics 2011;12(4):503-14
15. Mahlknecht U, Dransfeld CL, Bulut N, et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 2009;23(10):1929-32
16. Raynal C, Ciccolini J, Mercier C, et al. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. Ther Drug Monit 2010;32(1):53-60
17. Soo RA, Wang LZ, Ng SS, et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009;63(1):121-7
18. Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007;25(1):32-42
19. Mercier C, Evrard A, Ciccolini J. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results. J Clin Oncol 2007;25(30):4855; author reply 4855-6
20. Ciccolini J, Dahan L, Andre N, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 2010;28(1):160-5.
21. Giovannetti E, Tibaldi C, Falcone A, et al. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. J Clin Oncol 2010;28(14):e221-2; author reply e223-5
22. Peters GJ, Honeywell RJ, Maulandi M, et al. Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Nucleosides Nucleotides Nucleic Acids 2014;33(4-6):403-12
23. Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinumtreated advanced non-small-cell lung cancer patients. Ann Oncol 2012;23(3):670-7
24. Sugiyama E, Kaniwa N, Kim SR, et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet 2010;49(8):549-58.
25. Caronia D, Martin M, Sastre J, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 2011;17(7):2006-13
26. Mercier C, Raynal C, Dahan L, et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007;17(10):841-4
27. Serdjebi C, Ciccolini J, Fina F, et al. Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift? Pharmacogenet Genomics 2014;24(10):527-9
28. Ueno H, Kaniwa N, Okusaka T, et al. Homozygous CDA 3 is a major cause of life-threatening toxicities in gemcitabinetreated Japanese cancer patients. Br J Cancer 2009;100(6):870-3
29. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008;14(6):1797-803
30. Abraham A, Varatharajan S, Abbas S, et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 2012;13(3):269-82
31. Xu J, Zhou Y, Zhang J, et al. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation. Clin Chim Acta 2012;413(15-16):1284-7
32. Baker JA, Wickremsinhe ER, Li CH, et al. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos 2013;41(3):541-5
33. Mahfouz RZ, Jankowska A, Ebrahem Q, et al. Increased CDA expression/activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res 2013;19(4):938-48
34. Grepin R, Guyot M, Jacquin M, et al. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene 2012;31(13):1683-94
35. De Pas T, de Braud F, Danesi R, et al. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2000;11(7):821-7
36. Yonemori K, Ueno H, Okusaka T, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005;11(7):2620-4.
37. Ciccolini J, Evrard A, Lacarelle B. A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome-letter. Clin Cancer Res 2012;18(1):317
38. Sugiyama E, Lee SJ, Lee SS, et al. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Pharmacokinet 2009;24(6):553-6
39. Yardley DA. Gemcitabine and taxanes as a new standard of care in breast cancer. Clin Breast Cancer 2004;4(Suppl 3):S107-12
40. Sandler A, Ettinger DS. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 1999;4(3):241-51
41. Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for nonmuscle invasive bladder cancer (NMIBC): a systematic review. BJU Int 2012;109(4):496-505
42. Kroep JR, Giaccone G, Tolis C, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 2000;83(8):1069-76
43. Kim TM, Kim S, Ahn YO, et al. Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. Leuk Lymphoma 2014;55(4):940-3
44. Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17(Suppl 5):57-12
45. Serdjebi C, Seitz JF, Ciccolini J, et al. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics 2013;14(9):1047-51.
46. Farrell JJ, Bae K, Wong J, et al. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J 2012;12(5):395-403
47. Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2012;72(8):1111-36
48. Joerger M, Burgers SA, Baas P, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012;118(9):2466-75
49. Ciccolini J, Peters GJ, Giovannetti E. Gender, cytidine deaminase, and 5-aza/decitabine-letter. Clin Cancer Res 2013;19(11):3105
50. Fanciullino R, Serdjebi C, Mollard S, et al. Abstract 2208: cytidine deaminase deficiency and severe toxicities upon azacytidine intake: clinical observations and experimental evidences. Proceedings: AACR 104th Annual Meeting 2013; 6-10 April 2013; Washington, DC. Cancer Res 2013;73(8):abstract nr 2208
51. Falk IJ, Fyrberg A, Paul E, et al. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase. Am J Hematol 2013;88(12):1001-6
52. Xu PP, Chen BA, Feng JF, et al. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. Chin Med J (Engl) 2012;125(12):2137-43
53. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45(4):291-7
54. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34(8):1274-81
55. Morita T, Matsuzaki A, Kurokawa S, Tokue A. Forced expression of cytidine deaminase confers sensitivity to capecitabine. Oncology 2003;65(3):267-74
56. Dahan L, Ciccolini J, Evrard A, et al. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. J Clin Oncol 2012;30(4):e41-4
57. Andre F, Ciccolini J, Spano JP, et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics 2013;14(8):931-9
58. Mercier C, Dahan L, Ouafik L, et al. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 2010;66(9):959-60